PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31570424-10	2019	CONCLUSION: Results suggest that the anticancer activity of enoxaparin in A549 cells was mediated by the interference of two major PAR-1 downstream signaling pathways, MAPK/ERK and PI3K/Akt, which in turn inhibit proliferation and migration.	Enoxaparin	60-70	AKT serine/threonine kinase 1	Homo sapiens	186-189	
25488183-0	2015	Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.	Enoxaparin	0-10	AKT serine/threonine kinase 1	Homo sapiens	134-137	
25488183-10	2015	Additional enoxaparin administration resulted in better effective inhibition of Akt activity compared with gefitinib alone.	Enoxaparin	11-21	AKT serine/threonine kinase 1	Homo sapiens	80-83	
25488183-14	2015	Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression, Akt activity, and vimentin phosphorylation.	Enoxaparin	23-33	AKT serine/threonine kinase 1	Homo sapiens	140-143